Changxin Health Care Flexible Configuration Hybrid Fund(LOF)-A

Fosun Pharma Subsidiary's Levofloxacin Injection Approved

Fosun Pharma's Hengrui Medicine Receives Approval for Phase I Clinical Trial of HLX48 for Solid Tumors

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Fosun Pharma: Expected to submit NDA by year-end

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

Fosun Pharmaceutical's Subsidiary Receives Acceptance for Peach Red Four Ingredients Granule Drug Registration Application

Fosun Pharma Industry Acquires Exclusive Option from AriBio

Jiangsu Hengrui Medicine Signs $950 Million Global R&D Agreement with Bristol-Myers Squibb

Hengrui Medicine and Braveheart Bio Report Positive Phase 2 Results for HRS/BHB-1893 in Treating nHCM

Hengrui Medicine Receives Approval for Two Drug Clinical Trials

Fosun Pharma Subsidiary Approved for Phase I Clinical Trial of HLX05-N for Metastatic Colorectal Cancer in the US

Hengrui Pharmaceutical Obtains Clinical Trial Approval Notifications for Multiple New Drugs

Fosun Pharmaceutical's Subsidiary's Venlafaxine Hydrochloride Extended-Release Tablets Approved for Registration

159883

300888

163001

562600

159898

<p>Sunway Healthcare has appointed six investment banks as underwriters for its initial public offering (IPO), planning to list in Malaysia and expecting to raise over 3 billion Malaysian Ringgit, with a valuation exceeding 15 billion Malaysian Ringgit. The underwriters include Malayan Banking, Affin Hwang, CIMB, RHB, Kenanga, and Malaysia Investment Bank. The funds raised will be used for hospital expansion plans. Sunway Healthcare is one of Malaysia's leading private healthcare service providers, with approximately 1,805 beds</p>

Zaobao

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Winner Medical

ChinaAMC CSI All Share Health Care Devices ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Double Medical Health appoints six investment banks as underwriters for its IPO | Lianhe Zaobao

Changxin Health Care Flexible Configuration Hybrid Fund(LOF)-A(163001.SZ)

Double Medical Health appoints six investment banks as underwriters for its IPO | Lianhe Zaobao